Importance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma

Abstract

Background Complexities in TNM staging in epithelioid malignant pleural mesothelioma (MPM) may lead to errors in treatment selection, leading to major surgical interventions in patients with low survival expectations.

Methods Sixty-nine stage I epithelioid MPM patients, including 27 patients treated with pleurectomy/decortication (P/D) and multimodal therapy (MMT) (the P/D [MMT] group), and 42 patients treated with chemotherapy or chemoradiotherapy (the CRT group), were included in the study. After an initial evaluation of overall survival, all patients were grouped in terms of histopathological parameters and treatment types, and then, a secondary survival evaluation was performed for the groups.

Results Forty-one patients were male, the mean age was 61.8 years. The median survival time was 26 months in the P/D (MMT) group, and 19.6 months in the CRT group, but the difference was not statistically significant. After grouping according to pathological criteria, a median survival time of 32.4 ± 2.9 months in the P/D (MMT) group and 21.9 ± 3.2 months in the CRT group was obtained among patients with histopathological low-grade tumors. Among patients with high-grade tumors, the median survival time was 18.3 ± 2.6 months in the P/D (MMT) group and 17 ± 4.4 months in the CRT group. Among patients with low-grade tumors, the P/D (MMT) group had longer survival. Median survival times were similar among patients with high-grade tumors.

Conclusion In epithelioid MPM, histopathological grading by video-assisted thoracic surgery pleural biopsy can prove accurate in selecting patients for P/D and MMT.

Keywords

malignant pleural mesothelioma - histopathological grading - nuclear grading system - pleuretomy/decortication

Publication History

Received: 30 July 2022

Accepted: 06 December 2022

Article published online:
03 February 2023

• References

• 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366 (9483): 397-408
• 2 Nelson DB, Rice DC, Niu J. et al. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2018; 53 (05) 960-966
• 3 Bueno R, Opitz I. IASLC Mesothelioma Taskforce. Surgery in malignant pleural mesothelioma. J Thorac Oncol 2018; 13 (11) 1638-1654
• 4 Opitz I, Weder W. Pleural mesothelioma: is the surgeon still there?. Ann Oncol 2018; 29 (08) 1710-1717
• 5 Rusch VW, Chansky K, Kindler HL. et al; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol 2016; 11 (12) 2112-2119
• 6 Nowak AK, Chansky K, Rice DC. et al; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol 2016; 11 (12) 2089-2099
• 7 Hashimoto M, Takeuchi J, Takuwa T. et al. Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2019; 157 (01) 404-413
• 8 Kadota K, Suzuki K, Colovos C. et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 2012; 25 (02) 260-271
• 9 Rosen LE, Karrison T, Ananthanarayanan V. et al. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 2018; 31 (04) 598-606
• 10 Nicholson AG, Sauter JL, Nowak AK. et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 2020; 15 (01) 29-49
• 11 Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011; 6 (05) 896-904
• 12 Mlika M, Limam M, Benzarti A, Mezni F. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma. Adv Respir Med 2019; 87 (02) 90-95
• 13 Demirag F, Ünsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005; 128 (05) 3382-3387
• 14 Habougit C, Trombert-Paviot B, Karpathiou G. et al. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies. Virchows Arch 2017; 470 (06) 639-646
• 15 Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004; 78 (05) 1774-1776
• 16 Hashimoto M, Sato A, Kuroda A. et al. Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2020; 68 (08) 820-827
• 17 Rodríguez Panadero F. Diagnosis and treatment of malignant pleural mesothelioma. Arch Bronconeumol 2015; 51 (04) 177-184